Evolve Private Wealth LLC acquired a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 99,797 shares of the biopharmaceutical company

Emerald Investment Advisers LLC acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 31,750 shares of the biopharmaceuti

Bank of Nova Scotia bought a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,726,026 shares of the biopharmaceutical company

Kendall Capital Management acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 69,150 shares of the biopharmaceutical company

Callan Family Office LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 62,042 shares of the biopharmaceutical company

Commerce Bank purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 280,150 shares of the biopharmaceutical company

Earlier this month, Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS (iberdomide) plus daratumumab and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least one prior therapy. This marks the first FDA-approved cereblon-modulating protein degrader and the first multiple myeloma approval based on minimal residual disease-negative complete response, highlighting a new regulatory path for BMS’s oncology portfolio. We’ll now examine how this...

Ieq Capital LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm bought 1,252,740 shares of the biopharmaceutical company

Korea Investment CORP acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,501,534 shares

OVERSEA CHINESE BANKING Corp Ltd bought a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 27,062 shares of the biopharmaceutical company

EP Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 87,527 shares of the biopharmaceutical company

Blue Capital Inc. acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 18,381 shares of the biopharmaceutical company

B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 101,975 shares of the biopharmaceutical company

Keebeck Wealth Management purchased a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 16,581 shares of the biopharmaceutical company

Westpac Banking Corp acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 170,319 shares of the biopharmaceutical company

Shelter Mutual Insurance Co acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 53,800 shares of the biopharmaceutical company

NewEdge Wealth LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 18,530 shares of the biopharmaceutical company

Las acciones de Bristol Myers Squibb están recibiendo un impulso desde la aprobación de la FDA del 13 de agosto de 2026 y el segundo trimestre.